Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.3 USD | 0.00% | -0.27% | +509.29% |
May. 09 | Landos Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 02 | North American Morning Briefing : Stocks Seen -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 69.71M |
---|---|---|---|---|---|
Net income 2024 * | -26M | Net income 2025 * | -46M | EV / Sales 2024 * | - |
Net cash position 2024 * | 72.5M | Net cash position 2025 * | 30M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-9.49
x | P/E ratio 2025 * |
-13.2
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.54% |
1 week | -0.27% | ||
1 month | +3.62% | ||
3 months | +298.21% | ||
6 months | +454.73% | ||
Current year | +509.29% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Oakes
CEO | Chief Executive Officer | 56 | 22-06-20 |
Claudia Lopez
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Dawn Louro
CTO | Chief Tech/Sci/R&D Officer | - | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 57 | 17-08-31 | |
Tim Mayleben
BRD | Director/Board Member | 63 | 21-05-12 |
Alka Batycky
BRD | Director/Board Member | 54 | 23-05-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 22.3 | 0.00% | 5,739 |
24-05-15 | 22.3 | -0.67% | 12,273 |
24-05-14 | 22.45 | +1.10% | 2,461 |
24-05-13 | 22.2 | -0.56% | 3,896 |
24-05-10 | 22.33 | -0.13% | 10,749 |
Delayed Quote Nasdaq, May 16, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+509.29% | 69.71M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- LABP Stock